Sarepta Therapeutics Inc Stock Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 1.89B | Sales 2025 * | 2.89B | Capitalization | 12.35B |
---|---|---|---|---|---|
Net income 2024 * | 133M | Net income 2025 * | 1.18B | EV / Sales 2024 * | 6 x |
Net cash position 2024 * | 1.04B | Net cash position 2025 * | 2.61B | EV / Sales 2025 * | 3.37 x |
P/E ratio 2024 * |
59.2
x | P/E ratio 2025 * |
12.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.11% |
Latest transcript on Sarepta Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+307.09% | 8.43B |